What does it actually cost to buy a pharmacy?
The headline purchase price is only one line in the full cost of buying a pharmacy. The complete picture adds transaction taxes that vary significantly depending on deal structure, professional fees for legal and accounting due diligence, a working-capital buffer to bridge the NHS payment lag in the first weeks of ownership, and any fit-out or equipment spend the premises require. The return on that investment depends primarily on the NHS contract and dispensing volumes, not on the shop, the location, or retail footfall. Understanding the full cost stack before committing to professional fees and legal costs is the point of this post.
This is not an affordability guide (see first-time pharmacy buyer finance for the deposit, loan and post-tax cash-cover test) and it is not a due diligence guide (see pharmacy financial due diligence for the verification process). This post owns the cost stack and the investment question.
The cost stack, item by item
The table below shows the main cost lines for an illustrative pharmacy acquisition. The purchase price is labelled illustrative because no market figure is asserted here: a pharmacy's price is deal-specific and depends on the NHS contract, dispensing volumes and the structure of the deal. Every other figure is either HP-traceable or clearly qualitative.
| Cost line | What drives it | Illustrative amount (example only) | Source |
|---|---|---|---|
| Purchase price (goodwill-dominated) | NHS contract, dispensing item volumes, deal structure. Priced on a multiple of adjusted EBITDA and/or a pence-per-item benchmark; the actual multiple is deal-specific and is not asserted here. | £600,000 (illustrative) | HP 13, HP 16 |
| Transaction tax (share deal) | 0.5% stamp duty on the share consideration | £3,000 (0.5% of £600,000) | HP 12; gov.uk/tax-buy-shares |
| Transaction tax (asset deal, property element) | SDLT at non-residential bands: 0% to £150k, 2% £150k to £250k, 5% above £250k. On the same £600,000 (assuming the full consideration attracts SDLT): see section below. | £19,500 (illustrative; see breakdown below) | HP 12; gov.uk SDLT non-residential |
| Professional fees (legal and accounting) | Solicitor costs (heads of terms, SPA, regulatory consents), accounting due diligence, completion accounts. Costs vary by deal complexity and advisers chosen; no site price is stated. | Qualitative (deal-specific) | HP 16 |
| Working-capital buffer (NHSBSA payment lag) | FP34 submitted monthly; payment arrives roughly two months later with an advance on account. Day-one owners need a buffer to bridge this lag before normalised cash flow from the new FP34 cycle arrives. | Qualitative (depends on dispensing volumes) | HP 7; NHSBSA submitting prescriptions |
| Fit-out and equipment | Dispensary fit-out, robots, refrigeration, IT and security. Qualifying expenditure up to £1,000,000 can be claimed at 100% under the Annual Investment Allowance. Residual expenditure attracts WDA at 14% (main-rate pool) or 40% first-year allowance under FA 2026, or 6% (special-rate pool), or SBA at 3% on structural works. | Deal-specific; £0 to £100,000+ depending on condition of premises | HP 17, HP 18, HP 19 |
Illustrative total (share deal, £600,000 purchase price, minimal fit-out): purchase price £600,000 + stamp duty £3,000 + professional fees (qualitative) + working-capital buffer (qualitative). The transaction-tax line alone can shift by £16,500 depending on deal structure (see below). These figures are for illustration of the arithmetic only; the actual cost stack for any deal is specific to the price, structure, premises condition and advisers used.
Run your own scenario numbers through the pharmacy purchase affordability calculator. It models the cost stack and affordability test as a scenario estimate, states its simplifications, and routes complex situations to a specialist review.
The transaction-tax difference: share deal versus asset deal
The choice between buying shares and buying assets (see share versus asset purchase for the full treatment) has a direct impact on the transaction-tax cost. Using the same illustrative £600,000 purchase price:
Share deal
Stamp duty on shares is 0.5% of the consideration, payable on completion.
| Consideration | Rate | Tax (illustrative) |
|---|---|---|
| £600,000 | 0.5% | £3,000 |
Source: gov.uk/tax-buy-shares. A share deal also means the buyer inherits the company's full history, including any undisclosed liabilities, which is why due diligence scope on a share purchase is broader.
Asset deal (property element)
Where the deal includes a property element, SDLT applies at non-residential and mixed-use rates. The bands (which match the affordability calculator's logic exactly) are:
| SDLT band | Rate | Tax on that slice (illustrative, £600,000 total) |
|---|---|---|
| £0 to £150,000 | 0% | £0 |
| £150,001 to £250,000 | 2% | £2,000 |
| £250,001 to £600,000 | 5% | £17,500 |
| Total SDLT (illustrative) | £19,500 |
On the same illustrative £600,000 consideration, the asset deal costs £19,500 in SDLT versus £3,000 in stamp duty on a share deal. That is a £16,500 difference on transaction tax alone, before accounting for the fact that asset deals also mean the buyer does not inherit historical company liabilities. The right structure depends on the wider deal economics; the transaction-tax saving on a share deal must be weighed against the additional due diligence burden and risk profile.
Note also that on a company purchase, corporation tax relief on goodwill is restricted and only available in limited cases at fixed rates. That restriction is a further structuring consideration where goodwill dominates the purchase price, as it does on most pharmacy deals. See gov.uk guidance on CT relief on goodwill and the pharmacy purchase accounting service page for the full picture.
Is a pharmacy a good investment? The honest case
The investment case for a pharmacy rests on a specific set of structural strengths and a specific set of structural risks. Neither side of that equation is speculative: both are written into the Community Pharmacy Contractual Framework and the Drug Tariff.
The strengths
Income is contract-backed and recurring. A dispensing pharmacy's revenue is reimbursement (Drug Tariff prices for dispensed items) plus remuneration (fees and service payments under the CPCF). That income does not depend on retail footfall, marketing spend, or discretionary consumer behaviour. The NHS contract is the asset, not the shop. That recurring, contract-backed income stream is why a pharmacy can support acquisition finance in a way that many retail businesses cannot.
Service income is a growing revenue line. Pharmacy First and similar commissioned services are a separately accounted income line with their own fee structure. This line has grown as community pharmacy has taken on more primary-care-adjacent services, and it is structurally distinct from dispensing reimbursement. See NHS England's Pharmacy First pages and Pharmacy First income accounting for how this is accounted.
Demand is structurally resilient. Dispensing volumes are driven by the local population's prescription burden, not by discretionary spending. That does not make volumes risk-free (patient lists can move, GP practice changes can affect referral patterns), but the demand side is less volatile than most retail income.
The risks
Gross margin is set centrally and retrospectively adjusted. The Drug Tariff sets the reimbursement price for each dispensed item, and Category M clawbacks retrospectively adjust the margin on a significant proportion of the drug bill when actual purchase prices differ from the Drug Tariff assumptions. The owner does not control this margin. A pharmacy that looked profitable at the point of acquisition can face material margin compression from a Drug Tariff adjustment cycle that was not anticipated in the price paid. See Category M clawbacks explained and Drug Tariff changes explained.
The NHS payment cycle creates a structural cash-flow lag. FP34 prescriptions are submitted monthly and payment arrives roughly two months later. That lag is managed by an advance on account, but working-capital management is a permanent feature of operating a pharmacy, not just a day-one issue. Use the FP34 cash flow estimator to model what that lag means for a given volume of dispensing.
No invented return is stated here. The investment return on a pharmacy depends on the verified contract income, dispensing volumes, the price paid, and the cost of acquisition finance. No ROI, yield, or payback period applies across deals. Any figure quoted by a broker or seller as a typical return must be traced back to the actual FP34-reconciled income, adjusted EBITDA, and the price paid.
What the return actually depends on
A pharmacy's return is a function of three variables that a buyer can verify: the NHS contract and its stability, the dispensing item volume (items per month, verified against NHSBSA records), and the price paid relative to those fundamentals.
Goodwill dominates pharmacy pricing. The goodwill reflects the contract and item volume, not the premises, the shop fit, or the brand. A buyer is primarily paying for the right to dispense NHS prescriptions from that location under that contract. That is why regulatory due diligence (the NHS Pharmaceutical Regulations 2013 consent process, GPhC premises registration) sits alongside financial due diligence: without the contract and the registered premises, there is no asset.
Footfall, retail merchandising, and OTC sales can supplement income, but they are not what determines the return on the acquisition. The buyer who pays a price based primarily on retail upside rather than verified NHS contract income is misreading the asset.
The pharmacy goodwill: what it is worth post covers the mechanics of how goodwill is valued and what drives its price. The pharmacy financial due diligence post covers how to verify the income claims before exchange. This post covers the full cost of entry; those two posts cover verification and valuation.
Getting a real number for your deal
The cost stack in this post uses illustrative figures to show the arithmetic. The real numbers for any deal depend on the purchase price agreed, the structure chosen, the condition of the premises, the dispensing volumes, and the professional fees for the specific transaction.
Two tools that model your specific scenario:
- The pharmacy purchase affordability calculator models the cost stack, deposit requirement, loan affordability and post-tax cash cover for a given purchase price and projected income. It states its simplifications and is a scenario estimate, not a lending or filing decision.
- The FP34 cash flow estimator models the working-capital implications of the NHS payment lag at a given dispensing volume, helping you size the buffer needed at day one of ownership.
For the full picture, the pharmacy purchase accounting service page sets out what specialist support covers at each stage of a pharmacy acquisition, from early cost-stack modelling through due diligence, deal structuring and completion accounts. The buying a pharmacy hub links every resource in this lane.